Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T11163 |
EGFR-IN-9
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
EGFR-IN-9 是一种有效的 EGFR 激酶抑制剂,对于野生型 EGFR 激酶和双重突变型 EGFR 激酶 (L858R/T790M) 的 IC50 分别为 7 nM 和 28 nM。EGFR-IN-9 具有抗肿瘤活性。 | |||
T72854 |
EGFR/HER2-IN-9
|
||
EGFR/HER2-IN-9 是一种 EGFR 和 HER2抑制剂,对 EGFR、EGFR T790M 和 HER2 的 IC50分别为 3.2、8.3 和 14 nM。 | |||
T6136 |
Canertinib
PD-183805,CI-1033,卡纽替尼 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Canertinib (CI-1033) 是有效地,不可逆的EGFR 抑制剂;抑制细胞EGFR 和ErbB2自身磷酸化的IC50值分别为7.4和9 nM。 | |||
T73101 |
EGFR-IN-25
|
||
EGFR-IN-25 是一种有效的EGFR 抑制剂,对 BaF3 细胞 (EGFR DEL19/T790M/C797S) 和 A431 细胞 (WT) 的IC50分别为 9 nM 和 60 nM。 | |||
T69875 | ProMMP-9 inhibitor-3c | ||
ProMMP-9 inhibitor-3c is a potent and specific proMMP-9 inhibitor which disrupts f MMP-9 homodimerization and prevents association of proMMP-9 with both α4β1 integrin and CD44 and results in the dissociation of EGFR. | |||
T79651 |
EGFR-IN-83
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
EGFR-IN-83(化合物9)为EGFR抑制剂,IC50为2.53 nM。该化合物对MCF-7及MDA-MB-231细胞显示出抗增殖作用,其IC50值分别为2.50 μM及1.96 μM。此外,EGFR-IN-83能够诱导细胞凋亡。 | |||
T79152 |
PROTAC EGFR degrader 8
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
PROTACEGFRdegrader 8 (T-184) 是一种能够定向降解EGFR的PROTACEGFR降解剂,其在HCC827细胞中的DC50为15.56 nM。该化合物有效抑制多种肺癌细胞系,包括H1975、PC-9和HCC827,其IC50分别为7.72 nM、121.9 nM和14.21 nM。PROTACEGFRdegrader 8 主要用于研究非小细胞肺癌(NSCLC)。 | |||
T35897 |
ASK120067
|
||
ASK120067 is a potent and orally active inhibitor of EGFRT790M (IC50:0.3 nM) with selectivity over EGFRWT (IC50:6.0 nM). ASK120067 is a third-generation EGFR-TKI for the research of non-small cell lung cancer (NSCLC)[1]. In the in vitro kinase assay ASK120067 potently inhibits the EGFR L858R/T790M and EGFR T790M resistant mutants with IC50 values of 0.3 nM and 0.5 nM, respectively, as well as the EGFRexon19del sensitizing mutant (IC50= 0.5 nM). The 50 of ASK120067 against wild-type EGFR (EGFRWT... | |||
T36648 | Tucatinib hemiethanolate | ||
Tucatinib (Irbinitinib) hemiethanolate is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM. Tucatinib hemiethanolate has nanomolar activity against purified HER2 enzyme and is approximately 500-fold selective for HER2 versus EGFR in cell-based assays. Tucatinib selectively inhibits the receptor tyrosine kinase HER2 relative to EGFR[1].Tucatinib blocks proliferation and the phosphorylation of HER2 and its downstream effector, Akt in HER2 overexpressing cell lines. In the ... | |||
T35423 |
7-oxo Staurosporine
|
||
7-oxo Staurosporine is an antibiotic originally isolated from S. platensis with diverse biological activites. It inhibits PKC, PKA, phosphorylase kinase, EGFR, and c-Src in vitro (IC50s = 9, 26, 5, 200, and 800 nM, respectively). 7-oxo Staurosporine induces cell cycle arrest in the G2/M phase in human leukemia K562 cells with a minimal effective dose (MED) of 30 ng/ml. It is cytotoxic to P388 mouse leukemia cells that are resistant and susceptible to doxorubicin . 7-oxo Staurosporine inhibits gr... | |||
T37585 | Ensartinib | ||
Ensartinib (X-396) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively. The ability of Ensartinib (X-396) to inhibit the growth of different cancer cell lines harboring ALK fusions or point mutations is tested. Ensartinib is potent in H3122 lung cancer cells harboring EML4-ALK E13;A20 (IC50: 15nM). Ensartinib is also potent in H2228 lung cancer cells harboring EML4-ALK E6a/b; A20 (IC50: 45 nM). Furthermore, X-376 is potent in SUDHL-1 lymphoma cells harboring N... |